Delving into the Latest Updates on Shenzhen Yangli Pharmaceutical Technology Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Cardiovascular Diseases

Urogenital Diseases

Small molecule drug

siRNA

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	5
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	9
siRNA	2
Chemical drugs	1

Top 5 Target	Count

PARP1(Poly (ADP-Ribose) polymerase 1)	2
CDK2(Cyclin-dependent kinase 2)	1
ER(Estrogen receptors)	1
CYP11B2(Cytochrome P450 11B2)	1
Aldosterone	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

5

Preclinical

IND Approval

1

Phase 1

Phase 2

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

VB15010 ( PARP1 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
QLC1401	ER-positive/HER2-negative Breast Cancer More	Phase 1/2
VB19055 ( CYP11B2 )	Hypertension More	Phase 1
VB24	Hypertension More	Preclinical
VB18214 ( CDK2 )	Ovarian Cancer More	Preclinical